MYCOPLASMA PNEUMONIAE INFECTION IN PATIENTS WITH CHRONIC ASTHMA

慢性哮喘患者的肺炎支原体感染

• 批准号: 7718741
• 负责人: JAY PETERS
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718741
• 关键词: Acute; Antigens; Asthma; Bacteria; Bacterial Adhesins; Biological Assay; Blood; Chronic; Computer Retrieval of Information on Scientific Projects Database; Data; Detection; Development; Disease Progression; Frequencies; Functional disorder; Funding; Gold; Grant; Health Sciences; Infection; Institution; Irrigation; Link; Measurement; Mycoplasma; Mycoplasma pneumonia infection; Mycoplasma pneumoniae; Nose; Patients; Pharyngeal structure; Play; Polymerase Chain Reaction; Population; Purpose; Refractory; Research; Research Personnel; Resources; Respiratory physiology; Role; Sampling; Serological; Serum; Source; Sputum; Standards of Weights and Measures; Swab; Testing; Texas; Toxin; United States National Institutes of Health; Universities; Week; asthmatic patient; base; clinically relevant; improved; injured airway; pathogen; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: A bacterium, Mycoplasma pneumoniae, has been shown to occur frequently in the airways of patients with chronic asthma and during acute attacks of asthma. Treatment of this bacterium has also been shown to improve the lung function of thse asthmatics. Our research group at UTHSCSA (University of Texas Health Science Center at San Antonio) has discovered these bacteria produce a toxin that may injure the airway. Detection of the body's response to this toxin or measurement of this toxin in either blood or airway secretions may allow us to better understand the role that Mycoplasma plays in the development of asthma or the progression of the disease. Additionally, our preliminary data suggest that detections of the body's response to this toxin (called the CARDS Toxin) appears to be a much better way to detect Mycoplasma in the airways than the current "Gold" standard (called PCR to P1-adhesin). The purpose of this study is to determine the frequency of Mycoplasma (using the "Gold" standard assay and our newly discovered assay) in three populations of asthmatics: chronic, moderately severe asthmatics, asthmatics presenting with an asthma attack, and patients with refractory asthma. Further, we believe that the development and use of CARDS TX-based serological, antigen capture, and PCR assays will be a marked improvement in linking M. pneumoniae to asthma and other related airway dysfunctions. RESEARCH PLAN: We plan to serially study sputum, throat swabs, nasal lavage, and serum from asthmatic patients to determine the role of Mycoplasma in acute and chronic asthma. Additionally, we plan to compare the standard test for Mycoplasma to our newly developed assay. METHODS: Nasal lavage, throat swab and serum will be collected from all subjects at the beginning of the study and one year later. Any patient who is positive for Mycoplasma by PCR wil have repeat sampels every 8-12 weeks until two samples are negative. Stable asthmatics will have sputum induction performed if they are unable to provide 1 cc of sputum for analysis. CLINICAL RELEVANCE: Mycoplasma pneumoniae is a potential pathogen that may cause exacerbations of asthma or persistent chronic asthma. Persistent infection may be associated with refractory asthma. This study will enable us to better understand the relationship between Mycoplasma and acute and chronic asthma.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：肺炎支原体是一种常见于慢性哮喘患者气道和哮喘急性发作期的细菌。 这种细菌的治疗也被证明可以改善哮喘患者的肺功能。 我们在UTHSCSA（位于圣安东尼奥的德克萨斯大学健康科学中心）的研究小组发现，这些细菌产生一种可能损伤气道的毒素。 检测身体对这种毒素的反应或测量血液或气道分泌物中的这种毒素，可以使我们更好地了解支原体在哮喘发展或疾病进展中的作用。 此外，我们的初步数据表明，检测身体对这种毒素（称为P1毒素）的反应似乎是一种比目前的“黄金”标准（称为P1粘附素PCR）更好的检测气道中支原体的方法。 本研究的目的是确定支原体的频率（使用“金”标准检测和我们新发现的检测）在三个人群的哮喘：慢性，中度严重哮喘患者，哮喘发作的哮喘患者，难治性哮喘患者。 此外，我们相信，基于MTX的血清学、抗原捕获和PCR检测的开发和使用将是连接M的显著改进。肺炎与哮喘和其他相关气道功能障碍的关系。 研究报告：我们计划对哮喘患者的痰、咽拭子、鼻灌洗液和血清进行系列研究，以确定支原体在急性和慢性哮喘中的作用。 此外，我们计划将支原体的标准检测与我们新开发的检测进行比较。 方法：在研究开始时和一年后收集所有受试者的鼻灌洗液、咽拭子和血清。 任何PCR检测支原体阳性的患者将每8 - 12周重复采样一次，直到两个样本呈阴性。 如果稳定的哮喘患者无法提供1 cc痰液用于分析，则将进行痰液诱导。 临床相关性：肺炎支原体是一种可能导致哮喘加重或持续性慢性哮喘的潜在病原体。 持续感染可能与难治性哮喘有关。 这项研究将使我们更好地了解支原体与急性和慢性哮喘的关系。